Cited by

• 60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy.

  Cieri N, Maurer K, Wu CJ. Cieri N, et al. Cancer Res. 2021 Sep 1;81(17):4373-4384. doi: 10.1158/0008-5472.CAN-21-0301. Epub 2021 Jun 9. Cancer Res. 2021. PMID: 34108142 Free PMC article. Review.
• Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes.

  Falkenburg JH, Goselink HM, van der Harst D, van Luxemburg-Heijs SA, Kooy-Winkelaar YM, Faber LM, de Kroon J, Brand A, Fibbe WE, Willemze R, et al. Falkenburg JH, et al. J Exp Med. 1991 Jul 1;174(1):27-33. doi: 10.1084/jem.174.1.27. J Exp Med. 1991. PMID: 2056279 Free PMC article.
• Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells.

  Sykes M, Romick ML, Sachs DH. Sykes M, et al. Proc Natl Acad Sci U S A. 1990 Aug;87(15):5633-7. doi: 10.1073/pnas.87.15.5633. Proc Natl Acad Sci U S A. 1990. PMID: 2377601 Free PMC article.
• Post-transplant cyclophosphamide prevents xenogeneic graft-versus-host disease while depleting proliferating regulatory T cells.

  Ritacco C, Köse MC, Courtois J, Canti L, Beguin C, Dubois S, Vandenhove B, Servais S, Caers J, Beguin Y, Ehx G, Baron F. Ritacco C, et al. iScience. 2023 Jan 31;26(3):106085. doi: 10.1016/j.isci.2023.106085. eCollection 2023 Mar 17. iScience. 2023. PMID: 36843851 Free PMC article.
• Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities.

  Shi DD, Guo JA, Hoffman HI, Su J, Mino-Kenudson M, Barth JL, Schenkel JM, Loeffler JS, Shih HA, Hong TS, Wo JY, Aguirre AJ, Jacks T, Zheng L, Wen PY, Wang TC, Hwang WL. Shi DD, et al. Lancet Oncol. 2022 Feb;23(2):e62-e74. doi: 10.1016/S1470-2045(21)00596-9. Lancet Oncol. 2022. PMID: 35114133 Free PMC article. Review.